Target Sequencing and Resequencing Market

The Global Target Sequencing and Resequencing Market size was estimated at USD 10.70 billion in 2025 and is projected to reach USD 80.58 billion by 2035, growing at a CAGR of 22.37% from 2026 to 2035. The sector is becoming a core genomic infrastructure category as laboratories prioritize focused variant detection, lower sequencing waste, faster turnaround, and scalable precision-medicine workflows.

Key Highlights

• North America held the largest regional position, contributing more than 50% of global revenue in 2025 and retaining procurement leadership across clinical and research workflows.
• Sequencing accounted for more than 72% of revenue in 2025, establishing targeted sequencing workflows as the dominant technology pathway.
• The sector is advancing at a 22.37% CAGR through 2035 as precision oncology, rare-disease analysis, and molecular profiling expand genomic testing volumes.
• Academic research represented more than 50% of end-use revenue in 2025, reinforcing research institutions as major buyers of enrichment kits, sequencing workflows, and analytical tools.
• Automation, higher-throughput sequencing, and integrated enrichment-to-analysis workflows are reshaping laboratory economics by reducing manual intervention and shortening turnaround cycles.
• Clinical laboratories are shifting procurement toward integrated, reproducible workflows that connect target enrichment, sequencing, interpretation, and reporting rather than purchasing isolated workflow components.

Target Sequencing and Resequencing Market Overview

Target sequencing and resequencing have moved from specialized genomic research applications toward broader laboratory infrastructure supporting oncology, inherited disease analysis, biomarker discovery, drug development, and translational research. The commercial proposition centers on interrogating predefined genomic regions rather than allocating sequencing capacity across the entire genome, allowing buyers to control analytical scope, workflow complexity, and data-processing requirements.

Procurement decisions increasingly evaluate the complete workflow rather than an individual kit or instrument. Laboratories compare target capture performance, panel flexibility, compatibility with existing sequencers, sample-input requirements, automation options, bioinformatics integration, and downstream interpretation. This favors vendors capable of combining reagents, instruments, software, and technical support.

Clinical adoption also raises requirements for reproducibility, quality management, regulatory compatibility, and assay validation. Research customers generally prioritize flexibility and customization, while diagnostic laboratories place greater emphasis on standardized workflows and traceable performance. The resulting purchasing environment rewards platforms that reduce hands-on work while maintaining compatibility across established sequencing ecosystems.

The competitive structure therefore extends beyond sequencing instruments. Enrichment chemistry, library preparation, assay content, informatics, automation, and service delivery increasingly determine customer retention and workflow economics.

Key Market Drivers & Industrial Demand Dynamics

Precision oncology is a principal demand engine because targeted sequencing enables laboratories to concentrate analytical capacity on clinically relevant genes, mutations, fusions, copy-number alterations, and other biomarkers. Cancer research programs increasingly require repeatable molecular profiling across tissue and liquid-biopsy samples, creating procurement demand for fixed and customizable panels. Distributed testing models further expand the requirement for standardized enrichment and sequencing workflows. Commercially, this shifts purchasing from one-time instrument acquisition toward recurring reagent, panel, consumable, software, and service expenditure. Vendors with broad oncology content and compatible analytical infrastructure gain stronger account penetration because buyers prefer solutions that minimize validation effort and preserve workflow continuity across multiple cancer indications.

Rare-disease and inherited-disorder programs provide another structural demand source. Targeted sequencing allows laboratories to concentrate on clinically relevant genes or exonic regions when whole-genome approaches are unnecessary for the intended analytical objective. This creates a practical balance between genomic coverage, sample economics, analytical burden, and turnaround requirements. Diagnostic organizations increasingly require panels that can accommodate expanding gene lists without forcing complete workflow replacement. Flexible probe design and scalable enrichment architectures therefore become important procurement criteria. Suppliers that combine assay customization with established sequencing compatibility can support laboratories as disease-focused panels evolve, strengthening recurring reagent and service relationships.

Drug discovery and development are expanding the commercial addressable base because pharmaceutical and biotechnology organizations use targeted sequencing to characterize biomarkers, monitor molecular response, support translational studies, and investigate genomic drivers of disease. Companion-diagnostic development also connects sequencing providers with pharmaceutical development programs, where analytical consistency and regulatory readiness influence supplier selection. Outsourced sequencing and specialized laboratory services remain relevant where sponsors prefer variable capacity rather than maintaining complete internal infrastructure. The commercial consequence is a broader mix of consumable purchases, contract services, data analysis, and assay-development engagements. Suppliers able to provide flexible study designs and reproducible multi-site workflows gain relevance in decentralized drug-development programs.

Technology improvements are strengthening operational economics. Higher-throughput short-read platforms support large sample batches, while long-read systems address structural variation and complex genomic regions that conventional workflows handle less efficiently. Automation is also becoming more important as laboratories seek lower hands-on requirements and consistent library preparation. Illumina and SPT Labtech introduced fireflyGO in May 2026 to automate liquid handling and library preparation for targeted oncology research workflows connected with MiSeq i100 systems and Pillar Biosciences panels. These developments shift competition toward integrated workflow productivity rather than read generation alone.

A final demand driver is the expansion of distributed and interoperable genomic testing. Clinical laboratories increasingly require workflows that connect enrichment kits, sequencing instruments, interpretation software, and reporting environments. Illumina and Labcorp expanded their collaboration in March 2026 around distributed precision-oncology testing, including tissue and liquid-biopsy applications and development of additional genomic tests. Such models strengthen the business case for standardized targeted assays while bringing advanced testing closer to hospitals and community healthcare systems.

Segmentation Analysis

Target Sequencing and Resequencing Market, By Type

Sequencing and resequencing represent distinct workflow objectives. Sequencing focuses on interrogating predefined genomic targets for discovery, characterization, or diagnostic research, while resequencing compares known genomic regions against reference sequences to identify variants or changes. Sequencing accounted for the larger commercial position because new target panels, clinical profiling workflows, and research assays require recurring sequencing activity. Resequencing remains important where laboratories repeatedly examine established genomic regions, particularly in validation, population studies, and longitudinal investigations. Buyers generally prefer sequencing solutions offering flexible panel content and compatibility with installed instruments. Resequencing demand is supported by repeat testing and reference-driven workflows, making it an important specialized application rather than a substitute for broader targeted sequencing procurement.

Target Sequencing and Resequencing Market, By Target Material

DNA and RNA represent the primary target-material categories. DNA-based workflows maintain procurement leadership because they support variant detection, inherited-disease analysis, oncology profiling, exome-related applications, and many established research panels. RNA-based workflows address transcript fusions, expression-related investigations, transcriptomic biomarkers, and selected oncology applications. Buyer selection depends on biological question, sample quality, required sensitivity, and downstream interpretation. DNA remains the broader purchasing category because laboratories can deploy established hybrid-capture and amplicon architectures across a wide range of applications. RNA demand is expanding through fusion analysis and transcript-focused oncology research, creating opportunities for specialized panels and workflows optimized for degraded or limited samples.

Target Sequencing and Resequencing Market, By Targeting Method

Hybrid capture, amplicon sequencing, molecular inversion probes, and CRISPR-based enrichment address different requirements for target selectivity, panel size, sample characteristics, and workflow flexibility. Hybrid capture remains commercially prominent for broader panels and exome-scale target regions because probe libraries can cover extensive genomic territory while supporting customizable designs. Amplicon approaches offer streamlined workflows and efficient processing for focused panels, making them attractive where turnaround and simplicity dominate procurement decisions. Molecular inversion probes support highly targeted interrogation and multiplexing, while CRISPR-based approaches provide differentiated enrichment strategies for selected research applications. Buyer preference increasingly reflects total workflow cost, sample input, automation compatibility, and analytical depth rather than enrichment chemistry alone.

Target Sequencing and Resequencing Market, By Application

Clinical diagnostics, drug development, research and academia, and plant and animal sciences form the principal application groups. Clinical diagnostics represents the leading commercial application as molecular profiling expands across oncology, inherited disorders, and biomarker-driven testing. Drug-development programs use targeted sequencing to identify biomarkers, characterize mechanisms, and support translational research. Academic and research institutions remain major purchasers because targeted workflows provide focused datasets suitable for large study cohorts without requiring whole-genome sequencing for every experiment. Plant and animal sciences create a specialized demand base spanning breeding, disease research, population genetics, and agricultural genomics. Clinical applications favor standardized panels and regulated workflows, while research buyers prioritize customization, assay flexibility, and rapid experimental iteration.

Target Sequencing and Resequencing Market, By End User

Hospitals and diagnostic laboratories, pharmaceutical and biotechnology companies, academic and research institutions, and contract research organizations display distinct procurement behavior. Academic institutions historically form a major buyer group because genomic research programs require flexible target panels and recurring consumables. Diagnostic laboratories prioritize assay consistency, validation support, regulatory compatibility, and predictable turnaround. Pharmaceutical and biotechnology companies favor workflows that integrate biomarker analysis with drug-development programs and companion-diagnostic strategies. CROs require flexible capacity, multi-client workflows, and standardized processing across studies. The fastest commercial expansion is concentrated in clinical and pharmaceutical environments as targeted sequencing becomes embedded within precision oncology, biomarker development, and translational research programs.

Target Sequencing and Resequencing Market, By Region

North America remains the dominant regional market because of established sequencing infrastructure, high research expenditure, advanced clinical genomics capacity, and a deep ecosystem of sequencing, biotechnology, diagnostics, and pharmaceutical companies. Europe maintains strong demand through academic genomics, precision medicine programs, and regulated clinical laboratories, with procurement increasingly shaped by data governance and diagnostic compliance. Asia Pacific represents the fastest-expanding regional opportunity as sequencing capacity, biotechnology investment, and genomic research infrastructure broaden across major economies. Latin America is developing through reference laboratories, research institutions, and outsourced genomic services. Middle East & Africa remains smaller but presents opportunities where centralized laboratories and specialized genomic centers reduce the need for every institution to maintain complete sequencing infrastructure.

Strategic Market Snapshot

The commercial structure is shifting from standalone sequencing equipment toward integrated genomic workflows combining enrichment, library preparation, sequencing, bioinformatics, and interpretation. Buyers increasingly evaluate throughput, assay flexibility, sample compatibility, automation, and lifecycle economics together. Targeted oncology remains one of the most commercially actionable areas because laboratories require repeatable genomic profiling while managing tissue limitations and turnaround expectations.

The competitive environment is also widening beyond traditional sequencing-platform suppliers. Enrichment specialists, assay developers, bioinformatics providers, automation companies, and laboratory service organizations are capturing value at different workflow stages. This creates partnership opportunities but also raises switching costs for customers embedded in integrated ecosystems.

Long-read sequencing adds another layer of differentiation by addressing structural variants and complex genomic regions. At the same time, short-read platforms retain broad procurement relevance because of established installed bases, throughput, and mature assay ecosystems. The strongest commercial positions therefore combine workflow compatibility, assay breadth, informatics integration, and dependable consumable supply.

Value Chain, Cost Structure & Procurement Intelligence

The value chain begins with sample preparation and target enrichment, followed by library construction, sequencing, bioinformatics, interpretation, and reporting. Costs vary according to panel complexity, sample quality, sequencing depth, batch size, instrument utilization, and the degree of automation. Reagent and consumable purchases create recurring expenditure, while instruments and automation generate larger capital commitments.

Procurement teams increasingly compare total cost per actionable sample rather than headline instrument pricing. Vendor economics are influenced by reagent utilization, workflow throughput, service contracts, software subscriptions, technical support, and validation requirements. Laboratories with variable workloads often favor outsourced or hybrid models to avoid underutilized capital equipment. High-volume centers generally favor internal workflows where automation improves utilization and reduces labor intensity.

Procurement cycles are longer in regulated clinical settings because validation, quality documentation, interoperability, and regulatory status influence supplier qualification. Research organizations can move faster but place greater value on customization and experimental flexibility.

Market Restraints & Regulatory Challenges

Compliance requirements remain a central barrier to broader clinical deployment because targeted genomic testing involves sensitive patient information, assay validation, quality controls, and jurisdiction-specific regulatory expectations. Data privacy requirements influence cloud-based analysis and cross-border data transfer, while interoperability limitations complicate integration across sequencers, laboratory information systems, bioinformatics platforms, and reporting environments.

Deployment resistance also arises from fragmented workflows. Laboratories replacing established enrichment or sequencing processes face validation costs, staff training requirements, protocol changes, and potential disruption to ongoing studies. Sample quality creates another operational constraint, particularly for degraded FFPE material and low-input specimens.

Vendor dependence can increase enterprise risk when laboratories use proprietary reagents, closed software environments, or highly specialized panels. Buyers therefore increasingly assess supply continuity, open compatibility, technical support, cybersecurity, and transition pathways alongside analytical performance.

Market Opportunities & Outlook 2026–2035

Enterprise AI expansion creates opportunities across variant interpretation, workflow monitoring, quality-control automation, and genomic knowledge management. AI-enabled analytics can reduce manual review requirements while connecting sequencing output with larger clinical or research datasets. Workflow automation provides a second opportunity by reducing hands-on library preparation and improving consistency across high-volume laboratories.

Vertical specialization will become increasingly important. Oncology, rare disease, reproductive genomics, infectious disease, and pharmaceutical biomarker programs require tailored panels and interpretation frameworks rather than generic sequencing solutions. Multilingual deployment will also support wider use of genomic reporting across geographically diverse healthcare systems.

Customer engagement transformation is emerging through distributed testing, digital ordering, automated result delivery, and integrated laboratory services. Providers that combine assay content with software, services, automation, and technical support can create deeper customer relationships. The strongest opportunities through 2035 will center on interoperable workflows that reduce operational complexity while preserving assay flexibility.

Regional Outlook

XX%Market
Share

XX%Market
Share

XX%Market
Share

XX%Market
Share

XX%Market
Share

Segmentation Analysis

A. Revenue Estimates and Forecast

Market estimates, forecast and CAGR for all the segments covered in the report from 2025 to 2035.

Spacer

B. Market Share Overview

Sequencing

Resequencing

DNA

Market share of all the segments covered in the report for base year 2025 and forecast year 2035.

Competitive Scenario

A. Company Market Share Analysis

2025

XX%

XX%

XX%

Illumina

Inc.

Thermo Fisher Scientific

Spacer

B. Geographic Revenue

North America

Europe

Asia Pacific

Latin America

Middle East Africa

Spacer

C. Business Segment Revenue

Category 1

Category 2

Category 3

Spacer

D. Company Revenue

Revenue

Regional Analysis

Regional & Country-Level Strategic Insights

North America remains the leading regional market, supported by advanced genomics infrastructure, pharmaceutical R&D, clinical laboratories, and established sequencing vendors. The United States anchors procurement activity, while Canada and Mexico provide additional research, clinical, and outsourced-testing opportunities. Institutional buyers increasingly prioritize integrated workflows and regulatory-ready solutions.

Europe combines strong academic sequencing capacity with expanding precision-medicine infrastructure. Germany, the United Kingdom, France, Italy, and Spain provide major demand centers, while Nordic countries and the Benelux Union support genomics research, biotechnology, and specialized laboratory services. Data governance and diagnostic compliance strongly influence platform selection.

Asia Pacific presents the strongest expansion opportunity. China, Japan, South Korea, Australia, and India are strengthening sequencing infrastructure, while Southeast Asian markets are expanding through centralized laboratory models and outsourced testing. Procurement increasingly balances capital expenditure with reagent availability and local technical support.

Latin America remains service-oriented, with Brazil and Argentina providing the largest regional demand centers. Outsourced sequencing and centralized testing models help laboratories access advanced capabilities without duplicating expensive infrastructure.

Middle East & Africa is developing through national genomics initiatives, specialist hospitals, research centers, and reference laboratories. Saudi Arabia and the UAE are positioned as regional hubs, while Egypt, Kuwait, and South Africa provide additional demand. Infrastructure localization and technical support remain important purchasing criteria.

Technology, Innovation & Derivative Trends

Generative AI is becoming relevant to genomic interpretation, literature synthesis, variant prioritization, and laboratory knowledge management. Its commercial value depends on controlled data environments, traceable outputs, and integration with validated analytical workflows rather than standalone experimentation.

Multimodal interaction is expanding as genomic datasets increasingly connect sequencing results with clinical, imaging, transcriptomic, proteomic, and spatial information. Illumina highlighted this direction in February 2026 through integrated multiomics applications spanning spatial transcriptomics, epigenomics, and proteomics for oncology research.

Retrieval-augmented generation can support evidence retrieval for variant interpretation while maintaining access to controlled genomic knowledge sources. Conversational analytics can simplify interaction with complex sequencing datasets. API interoperability is becoming more important as laboratories connect enrichment systems, instruments, cloud pipelines, laboratory information systems, and reporting applications.

Enterprise orchestration will therefore become a competitive differentiator, linking sample intake through final interpretation while minimizing manual transfers and fragmented software environments.

Competitive Landscape Overview

Competition is structured around sequencing platforms, enrichment technologies, assay content, bioinformatics, laboratory automation, and outsourced genomic services. Large suppliers pursue integrated workflows to increase customer retention, while specialized companies differentiate through enrichment chemistry, custom panels, long-read applications, or analytical software.

Pricing structures vary from capital equipment plus recurring consumables to reagent-led models, subscription software, per-sample services, and project-based outsourcing. Enterprise buyers increasingly evaluate workflow economics rather than isolated unit prices.

Integration capability is becoming a decisive factor because laboratories seek compatibility across sample preparation, enrichment, sequencing, analysis, and reporting. Partnerships are therefore commercially important where one supplier lacks complete workflow coverage. Twist Bioscience and Element Biosciences, for example, expanded collaboration in May 2025 around library preparation and target-enrichment workflows for Element sequencing systems.

Key Players

The competitive field comprises sequencing-platform providers, enrichment specialists, assay developers, bioinformatics companies, and laboratory-service organizations serving research and clinical workflows.

• Illumina, Inc.
• Thermo Fisher Scientific, Inc.
• Agilent Technologies, Inc.
• F. Hoffmann-La Roche Ltd.
• QIAGEN N.V.
• Integrated DNA Technologies, Inc.
• Pacific Biosciences of California, Inc.
• Oxford Nanopore Technologies plc
• BGI Genomics Co., Ltd.
• Bio-Rad Laboratories, Inc.
• Twist Bioscience Corporation
• 10x Genomics, Inc.

Recent Developments — 2025–2026

The competitive landscape has increasingly emphasized automation, integrated enrichment, oncology specialization, and distributed testing.

• May 2026 — Illumina and SPT Labtech introduced fireflyGO, automating library preparation and liquid handling for targeted oncology research workflows and strengthening end-to-end laboratory automation.
• March 2026 — Illumina and Labcorp expanded their collaboration around distributed precision-oncology testing, supporting broader access to tissue and liquid-biopsy genomic testing.
• February 2026 — Illumina expanded its multiomics portfolio around spatial transcriptomics, epigenomics, proteomics, and multimodal analysis, widening the analytical context surrounding targeted genomic workflows.
• February 2026 — Illumina announced NovaSeq X performance enhancements covering output, speed, and data quality, strengthening sequencing productivity for high-throughput genomic programs.
• December 2025 — Wasatch BioLabs and Agilent announced a co-marketing agreement combining Agilent enrichment chemistries with a native-read Oxford Nanopore workflow for targeted multi-omic analysis.
• May 2025 — Twist Bioscience and Element Biosciences expanded collaboration on library preparation and target-enrichment workflows for Element sequencing systems, supporting integrated NGS procurement.
• February 2025 — Biofidelity announced Enspyre, a target-enrichment technology designed to selectively enrich specified variants before sequencing, broadening targeted sample-preparation options.

Methodology & Data Credibility

The report applies bottom-up modeling supported by demand-side validation, supply-side validation, executive interviews, and cross-region verification. Market estimates are constructed by evaluating sequencing workflow economics, reagent utilization, installed infrastructure, application demand, procurement structures, and supplier activity across major geographic markets.

Triangulation reconciles company-level evidence, industry data, technology adoption patterns, institutional procurement behavior, and application-specific demand. Executive interviews are used to validate workflow priorities, purchasing criteria, implementation barriers, and technology transition patterns. Demand-side validation incorporates clinical laboratories, pharmaceutical organizations, academic institutions, and research service providers. Supply-side validation assesses platform availability, enrichment portfolios, reagent ecosystems, service capacity, and technology development.

Cross-region verification supports consistency across regulatory, infrastructure, pricing, and deployment environments while reducing dependence on any single data source.

Who Should Read This Report

This report is designed for executives and decision-makers across sequencing technology, molecular diagnostics, biotechnology, pharmaceuticals, laboratory services, genomics, and healthcare research. It supports strategy leaders evaluating market-entry opportunities, product managers planning sequencing or enrichment portfolios, procurement teams benchmarking supplier capabilities, and investors assessing genomic infrastructure opportunities.

Clinical laboratory executives can use the analysis to evaluate workflow modernization and distributed testing strategies. Pharmaceutical organizations can assess biomarker and companion-diagnostic infrastructure. Biotechnology companies can benchmark assay and enrichment opportunities. Academic and research institutions can compare technology architectures, service models, and procurement structures.

The report also supports consultants, corporate-development teams, technology vendors, distributors, and investors requiring a structured view of demand drivers, competitive positioning, regional opportunities, and emerging genomic workflow economics.

What This Report Delivers

The report delivers a structured assessment of market size, forecast trajectory, segmentation, regional positioning, competitive dynamics, technology development, procurement behavior, and strategic opportunities through 2035. It distinguishes sequencing and resequencing requirements while mapping DNA and RNA workflows, enrichment architectures, application demand, end-user procurement, and regional development.

The analysis identifies the commercial factors shaping laboratory purchasing decisions, including workflow integration, automation, sample requirements, assay flexibility, bioinformatics compatibility, regulatory readiness, and recurring consumable economics. It also evaluates the implications of clinical genomics expansion, pharmaceutical biomarker programs, precision oncology, research applications, and outsourced sequencing.

Decision-makers receive an enterprise-oriented framework for assessing supplier positioning, technology investments, partnership opportunities, regional expansion, workflow modernization, and long-term portfolio priorities.

Target Sequencing and Resequencing Market Report Segmentation

• By Type:
  • Sequencing
  • Resequencing
• By Target Material:
  • DNA
  • RNA
• By Targeting Method:
  • Hybrid Capture
  • Amplicon Sequencing
  • Molecular Inversion Probes
  • CRISPR-Based Enrichment
• By Application:
  • Clinical Diagnostics
  • Drug Development
  • Research & Academia
  • Plant & Animal Sciences
• By End User:
  • Hospitals & Diagnostic Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutions
  • Contract Research Organizations
• By Region:
  • North America: United States, Canada, Mexico
  • Europe: Germany, United Kingdom, France, Italy, Spain, Nordic Countries, Benelux Union, Rest of Europe
  • Asia Pacific: China, India, Japan, New Zealand, South Korea, Australia, Southeast Asia, Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Rest of Latin America
  • Middle East & Africa: Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa